Literature DB >> 19535177

Novel N-(3-carboxyl-9-benzyl-beta-carboline-1-yl)ethylamino acids: synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation.

Jianhui Wu1, Ming Zhao, Keduo Qian, Kuo-Hsiung Lee, Susan Morris-Natschke, Shiqi Peng.   

Abstract

Sixteen novel N-(3-carboxyl-9-benzyl-beta-carboline-1-yl)ethylamino acids (6a-p) were synthesized as intercalating lead compounds. In the in vitro cytotoxic assay their IC(50) values against five human carcinoma cell lines ranged from 10.95 microM to about 400 microM. On S180 mouse model eight of them exhibited anti-tumor action, four of them showed the same anti-tumor potency as that of cytarabine. The preliminary toxicity evaluation revealed that the LD(50) values of 6a-p should be more than 500 mg/kg. With CT DNA as model system an intercalating mechanism was explored. Using 3D QSAR analysis the relationship of the in vivo anti-tumor activity and the structure was quantitatively described. By docking 6a-p onto d(CGATCG)(2) oligonucleotides the intercalation was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535177     DOI: 10.1016/j.ejmech.2009.05.006

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.

Authors:  Ji Liu; Tingting Wang; Xinyang Wang; Lin Luo; Jing Guo; Yanfu Peng; Qibing Xu; Jiefei Miao; Yanan Zhang; Yong Ling
Journal:  Medchemcomm       Date:  2017-03-29       Impact factor: 3.597

2.  Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents.

Authors:  Shivaputra A Patil; James K Addo; Hemantkumar Deokar; Shan Sun; Jin Wang; Wei Li; D Parker Suttle; Wei Wang; Ruiwen Zhang; John K Buolamwini
Journal:  Drug Des       Date:  2017-03-01

3.  N-(3-hydroxymethyl-β-carboline-1-yl-ethyl- 2-yl)-l-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation.

Authors:  Jianhui Wu; Ming Zhao; Yuji Wang; Yaonan Wang; Haimei Zhu; Shurui Zhao; Lin Gui; Xiaoyi Zhang; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2017-01-17       Impact factor: 4.162

4.  Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents.

Authors:  Xiaofei Chen; Liang Guo; Qin Ma; Wei Chen; Wenxi Fan; Jie Zhang
Journal:  Molecules       Date:  2019-08-14       Impact factor: 4.411

Review 5.  Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations.

Authors:  Sheng Tang; Zhihui Zhou; Zhiyan Jiang; Wufu Zhu; Dan Qiao
Journal:  Molecules       Date:  2022-02-28       Impact factor: 4.411

6.  Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis.

Authors:  Shan Li; Yuji Wang; Feng Wang; Yaonan Wang; Xiaoyi Zhang; Ming Zhao; Qiqi Feng; Jianhui Wu; Shurui Zhao; Wei Wu; Shiqi Peng
Journal:  Int J Nanomedicine       Date:  2015-08-24

7.  Design, synthesis and biological evaluation of hybrids of β-carboline and salicylic acid as potential anticancer and apoptosis inducing agents.

Authors:  Qi-Bing Xu; Xiang-Fan Chen; Jiao Feng; Jie-Fei Miao; Ji Liu; Feng-Tao Liu; Bi-Xi Niu; Jin-Yang Cai; Chao Huang; Yanan Zhang; Yong Ling
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

8.  Docking of THPDTPI: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent.

Authors:  Haimei Zhu; Yuji Wang; Ce Song; Qiqi Feng; Jianhui Wu; Shurui Zhao; Lin Gui; Xiaoyi Zhang; Ming Zhao; Shiqi Peng
Journal:  Oncotarget       Date:  2017-07-19

9.  Neglschisandrins E-F: two new lignans and related cytotoxic lignans from Schisandra neglecta.

Authors:  Min Chen; Xiumei Xu; Bing Xu; Panpan Yang; Zhihua Liao; Susan L Morris-Natschke; Kuo-Hsiung Lee; Daofeng Chen
Journal:  Molecules       Date:  2013-02-19       Impact factor: 4.411

10.  Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors.

Authors:  Haiyan Chen; An Lu; Xiaoyi Zhang; Lin Gui; Yaonan Wang; Jianhui Wu; Hua Feng; Shiqi Peng; Ming Zhao
Journal:  Drug Des Devel Ther       Date:  2018-07-09       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.